Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Royal Bank of Canada (RY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Royal Bank of Canada — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Royal Bank of Canada trades at $206.39 (market cap $290.60B). The key difference: Royal Bank of Canada is far larger — about 64.7× ACADIA Pharmaceuticals Inc.'s market cap, and Royal Bank of Canada pays a 2.44% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | RY | |
|---|---|---|
Market Cap | $4.49B | $290.60B |
Sector | Health | Financials |
52-Week High | $28.06 | $209.07 |
52-Week Low | $20.06 | $128.46 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Royal Bank of Canada (RY) trades at $209.07, up 2.09% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 31.85% net income margin and 17.17% ROE, supported by a $1.76 quarterly dividend and a share repurchase program. Revenue grew to $66.53B in 2025, and cash flow trends indicate improving operational strength.
RY presents a solid investment case with consistent profitability and shareholder returns, though valuation metrics like a P/E of 19.2 and P/B of 3.17 suggest premium pricing. Risks include economic sensitivity and high debt levels, but analyst consensus leans positive with 43% buy ratings. The outlook remains favorable if earnings growth persists amid macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
